1. Home
  2. NOMD vs LTGO Comparison

NOMD vs LTGO Comparison

Compare NOMD & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nomad Foods Limited

NOMD

Nomad Foods Limited

SELL

Current Price

$11.48

Market Cap

1.5B

ML Signal

SELL

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$14.70

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NOMD
LTGO
Founded
2014
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
NOMD
LTGO
Price
$11.48
$14.70
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$13.74
★ $52.25
AVG Volume (30 Days)
★ 1.2M
359.3K
Earning Date
11-05-2026
11-19-2026
Dividend Yield
★ 6.01%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.31
N/A
P/E Ratio
$8.38
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.99
$13.85
52 Week High
$13.08
$25.93

Technical Indicators

Market Signals
Indicator
NOMD
LTGO
Relative Strength Index (RSI) 60.30 35.48
Support Level $10.99 $14.60
Resistance Level $12.16 $16.56
Average True Range (ATR) 0.30 1.25
MACD 0.12 -0.18
Stochastic Oscillator 83.45 24.46

Price Performance

Historical Comparison
NOMD
LTGO

About NOMD Nomad Foods Limited

Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: